Myriad Genetics, Inc.
MYGN
Get informed when a big investor buys or sells
+ FollowMarket Cap$583.69M
Close$
$-2.03
136.1% downside
Current Fair Value
136.1% downsideOvervalued by 136.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $583.69 Million |
|---|---|
| Enterprise Value | $670.79 Million |
| Dividend Yield | $3.50 (-) |
| Earnings per Share | $-3.96 |
| Beta | 1.64 |
| Outstanding Shares | 93,700,000 |
Return
| Return on Equity | -118.52% |
|---|---|
| Return on Assets | -59.36% |
| Return on Invested Capital | -71.02% |
Valuation & Multiples
| P/E Ratio | -1.44 |
|---|---|
| PEG | 0 |
| Price to Sales | 0.7 |
| Price to Book Ratio | 1.87 |
| Enterprise Value to Revenue | 0.81 |
| Enterprise Value to EBIT | -1.74 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.32 |
| Debt to Equity | 0.63 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 5, 2026
EPS Estimate
$-0.06
Average shareholder expectationRevenue Estimate
$202.42 M
Average shareholder expectationNext Earnings Call
Expected Date
August 4, 2026
EPS Estimate
$-0.03
Average shareholder expectationRevenue Estimate
$206.03 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 82.61% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.23%▼ 226.93% |
|---|---|
| Total Invested | $6.59M▼ 98.73% |
| Investors Holding | 15▼ 189.00% |
ESG Score
No data
About Myriad Genetics, Inc.
2,600 employees
CEO: R. Bryan Riggsbee Myriad Genetics Inc., is a leading genetic testing and precision medicine company dedicated to transforming patient lives worldwide. Myriad discovers and commercializes genetic tests that: determine the risk of developing disease, accura...